Patents Examined by Scarlett Goon
  • Patent number: 9770407
    Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: September 26, 2017
    Assignee: LUNDBECK PHARMACEUTICALS LLC
    Inventors: James Cloyd, Angela Birnbaum, Ilo Leppik, Stephen D. Collins
  • Patent number: 9629797
    Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 25, 2017
    Assignee: LUNDBECK PHARMACEUTICALS LLC
    Inventors: James Cloyd, Angela Birnbaum, Ilo Leppik, Stephen D. Collins
  • Patent number: 9593102
    Abstract: Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: March 14, 2017
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Coo-Min Chung, Hyung-Jin Jun, Jin-Sung Kim, Hui-Ho Kim, Hye-Kyung Min, Yong-Gil Kim, Jong-Gil Choi, Hongwook Kim
  • Patent number: 9539272
    Abstract: This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 10, 2017
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Paul A. Marks, Weisheng Xu, Mandana Namdar
  • Patent number: 9539215
    Abstract: A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: January 10, 2017
    Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: George John, Praveen Vemula
  • Patent number: 9522129
    Abstract: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: December 20, 2016
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Patent number: 9518077
    Abstract: The present disclosure provides methods for producing chitosan derivatives and the derivatives formed by these methods. The processes of the present disclosure utilize electrochemical methods to functionalize and/or modify amine and/or hydroxyl groups present on chitosan, to form new derivatives. In embodiments, a chloro-chitosan derivative may be prepared. The altered cationic affinity of these derivatives make them excellent candidates for biomedical applications, including pharmaceuticals, as well as food applications.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 13, 2016
    Assignee: The Research Foundation for the State University of New York
    Inventors: Gary P. Halada, Prashant Kumar Jha
  • Patent number: 9504747
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 29, 2016
    Assignee: Novartis AG
    Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
  • Patent number: 9492550
    Abstract: The presently disclosed and claimed inventive concept(s) relates to a polymer for enhancing drug performance and improving processability. Specifically, the polymer comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS). On the HPMC-AS, the percentage of total succinoyl degree of substitution is less than 12% at C6-OH position and greater than 53% at C3-OH, and the percentage of total acetyl degree of substitution is greater than 32% at C6-OH position.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: November 15, 2016
    Assignee: Hercules LLC
    Inventors: Todd A. Brugel, Tuyen T. Nguyen, Sangrama Sahoo, Divya Tewari, Yuda Zong
  • Patent number: 9464022
    Abstract: A method of transforming biomass into lactic acid using modified beta zeolites is disclosed. The one-step preparation process of preparing catalyst in the invention is mild, economical and convenient. The biomass used as precursor is economic and easy to get. Meanwhile, the reaction process doesn't need to be protected by noble gases with high pressure. The catalyst can be reused and the yield of lactic acid is high.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: October 11, 2016
    Assignee: TONGJI UNIVERSITY
    Inventors: Yalei Zhang, Zheng Shen, Wenjie Dong, Xuefei Zhou
  • Patent number: 9464166
    Abstract: In a process for producing 3,4? and/or 4,4? dimethyl-substituted biphenyl compounds, a feed comprising toluene is contacted with hydrogen in the presence of a hydroalkylation catalyst under conditions effective to produce a hydroalkylation reaction product comprising (methylcyclohexyl)toluenes. At least part of the hydroalkylation reaction product is dehydrogenated in the presence of a dehydrogenation catalyst under conditions effective to produce a dehydrogenation reaction product comprising a mixture of dimethyl-substituted biphenyl isomers. The dehydrogenation reaction product is then separated into at least a first stream containing at least 50% of 3,4? and 4,4? dimethylbiphenyl isomers by weight of the first stream and at least one second stream comprising one or more 2,x? (where x? is 2?, 3?, or 4?) and 3,3? dimethylbiphenyl isomers.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 11, 2016
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Jihad M. Dakka, Lorenzo C. DeCaul, Keith H. Kuechler, Neeraj Sangar, Michael Salciccioli, Alan A. Galuska, Gary D. Mohr
  • Patent number: 9453040
    Abstract: A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: September 27, 2016
    Assignee: IMPERIAL INNOVATIONS LIMITED
    Inventors: Sunil Shaunak, Ian Alfred Teo
  • Patent number: 9439915
    Abstract: Described herein are compositions useful in anticancer treatment. The compositions are composed of (a) an O2-aryl substituted diazeniumdiolate and (b) an amphiphile, wherein the amount of amphiphile is sufficient to produce a liposome or micelle. The compositions described herein provide numerous advantages such as increased solubility and stability of the O2-aryl substituted diazeniumdiolate in vivo. The compositions also do not induce hypotension. Methods for using the compositions in anticancer treatment are also described herein.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: September 13, 2016
    Assignee: University of Utah Research Foundation
    Inventors: Paul J. Shami, Ken M. Kosack
  • Patent number: 9399655
    Abstract: A catalytic glycosylation method comprising: installing thioether to an anomeric carbon of a carbohydrate; and catalytically activating the thioether with a non-oxophilic Lewis acid. The thioether may comprise an anomerically stable thioether leaving group. The catalytic glycosylation method may further comprise: utilizing an acid-sensitive ester protecting group as permanent protecting group or using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process. A protecting group to mask hydroxyl functionalities in the production of oligosaccharides, natural products or any molecule having a hydroxyl group comprising an acid-labile ester protecting group.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: July 26, 2016
    Assignee: University of Pittsburgh—Of The Commonwealth System of Higher Education
    Inventor: Xinyu Liu
  • Patent number: 9394219
    Abstract: Method for producing synthesis gas for methanol production The present invention relates to a method for producing synthesis gas from a hydrocarbon containing feed, which synthesis gas is particularly suitable for subsequent use in methanol production. In this method, a hydrocarbon containing feed, particularly natural gas (100), is subjected to catalytic partial oxidation (CPO) (2), followed by the water gas shift (WGS) (4) reaction of a part of the reformed feed. At least part of the shifted feed is then subjected to hydrogen purification, preferably by pressure swing adsorption (PSA) (5) to obtain pure hydrogen (108), which hydrogen is subsequently combined with the remaining parts of the feeds to yield synthesis gas particularly suitable for methanol synthesis. The recombined stream preferably has an R ratio, being the molar ratio (H2?CO2)/(CO+CO2), in the range 1.9-2.2 and preferably about 2.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: July 19, 2016
    Assignee: STAMICARBON B.V.
    Inventors: Gaetano Iaquaniello, Barbara Cucchiella, Elena Antonetti
  • Patent number: 9388109
    Abstract: With respect to reduced coenzyme Q10, there has been no report about the presence of crystal polymorphism, and it has been considered that a conventionally obtained crystal form is only one form. The present invention relates to a reduced coenzyme Q10 crystal having an endothermic peak indicating melting at 54±2° C. during temperature rise at a rate of 5° C./min by differential scanning calorimetry (DSC), and/or to a reduced coenzyme Q10 crystal showing characteristic peaks at diffraction angles (2?±0.2°) of 11.5°, 18.2°, 19.3°, 22.3°, 23.0° and 33.3° by powder X-ray (Cu—K?) diffraction. The crystal form is a novel reduced coenzyme Q10 crystal which has a higher melting point and a lower solubility in a solvent, and is more excellent in stability than the conventionally known reduced coenzyme Q10 crystal.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: July 12, 2016
    Assignee: KANEKA CORPORATION
    Inventors: Hideo Kawachi, Shiro Kitamura, Yasuyoshi Ueda
  • Patent number: 9382177
    Abstract: A process is disclosed for producing ethanol, comprising contacting hydrogen and a feed stream comprising acetic acid in a reactor in the presence of a catalyst comprising a binder and a mixed oxide comprising a promoter metal and tin, and preferably also comprising cobalt. The promoter metal is selected from the group consisting of rhenium, ruthenium, rhodium, palladium, osmium, iridium, platinum, and combinations thereof. The feed stream may comprises pure acetic acid or may comprise a mixture of 50 to 95 wt. % acetic acid and 5 to 50 wt. % ethyl acetate.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: July 5, 2016
    Assignee: CELANESE INTERNATIONAL CORPORATION
    Inventors: Zhenhua Zhou, Victor J. Johnston, Heiko Weiner
  • Patent number: 9376647
    Abstract: The present invention relates to novel non-aqueous gels of natural oils and their derivatives and provides a novel process for the gelation of natural oils and their derivatives that does not require the addition of gellants or the irreversible heat bodying of the oil. The gels and method of the present invention are applicable to a wide range of natural oils, and the method is easily tailored to provide thermoreversible gels of any desired viscosity. The natural oil based gels of the present invention and the method of their preparation have many advantages over the prior art. The natural oil based gels provided have exemplary properties and find use in a variety of applications.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: June 28, 2016
    Assignee: Ethox Chemicals, LLC
    Inventor: James T. Tanner
  • Patent number: 9371316
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: June 21, 2016
    Assignee: Asana Biosciences, LLC
    Inventors: Roger Astbury Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Patent number: 9371398
    Abstract: Provided is a method for efficiently preparing alkali cellulose having a uniform alkali distribution. More specifically, provided are a methods for preparing alkali cellulose comprising a contact filtration step of bringing a pulp into contact with an alkali metal hydroxide solution on a moving filtration plane for vacuum filtration to collect a contact product remaining on the filtration plane, and a draining step of draining the contact product; and a method of preparing cellulose ether by using the alkali cellulose. Also provided is an apparatus for preparing alkali cellulose comprising a continuous horizontal vacuum filter type contactor.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: June 21, 2016
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventor: Mitsuo Narita